AI Article Synopsis
- A young female patient developed severe hypophosphatemia and mild muscle weakness after receiving an intravenous iron infusion for iron-deficiency anemia.
- The hypophosphatemia was linked to elevated levels of Fibroblast Growth Factor 23 (FGF23), which causes renal phosphate loss.
- FGF23 inhibits the reabsorption of phosphate in the kidneys and the activation of vitamin D, reducing phosphate absorption from the intestines, while symptoms may be less noticeable following iron replacement therapy.
Article Abstract
After a young female patient received an intravenous iron infusion for severe symptomatic iron-deficiency-anemia, a severe hypophosphatemia was diagnosed with associated mild muscle weakness. With renal phosphate loss and elevated serum FGF23 (Fibroblast Growth Factor 23), the diagnosis of a hypophosphatemia caused by ferric carboxymaltose was made. Upregulation of FGF23 inhibits renal phosphate reabsorption and also the activation of vitamin D, which additionally reduces intestinal phosphate absorption. The symptoms of hypophosphatemia may be masked after iron replacement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23785/PRAXIS.2024.09.004 | DOI Listing |
Publication Analysis
Top Keywords
intravenous iron
8
renal phosphate
8
[muscle weakness
4
weakness intravenous
4
iron replacement]
4
replacement] young
4
young female
4
female patient
4
patient received
4
received intravenous
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!